busulfan has been researched along with Blood Clot in 31 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Therapeutic options for patients with polycythemia vera (PV) and essential thrombocythemia (ET) resistant or intolerant to hydroxyurea are limited." | 9.19 | Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. ( Alvarez-Larrán, A; Ancochea, A; Angona, A; Antelo, ML; Bellosillo, B; Besses, C; Burgaleta, C; Cervantes, F; Durán, MA; Ferrer-Marín, F; Gómez, M; Gómez-Casares, MT; Hernández-Boluda, JC; Marcote, B; Martínez-Avilés, L; Martínez-Trillos, A; Mata, MI; Senín, A; Vicente, V; Xicoy, B, 2014) |
| " From 1974 to 1986 we treated 20 symptomatic ET patients with microvascular circulation disturbances including erythromelalgia (N = 18), atypical or typical transient ischemic attacks (N = 6), or acute coronary ischemic syndrome (N = 3) with aspirin and one course of busulfan." | 9.09 | Normal life expectancy and thrombosis-free survival in aspirin treated essential thrombocythemia. ( Michiels, JJ, 1999) |
| "Therapeutic options for patients with polycythemia vera (PV) and essential thrombocythemia (ET) resistant or intolerant to hydroxyurea are limited." | 5.19 | Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. ( Alvarez-Larrán, A; Ancochea, A; Angona, A; Antelo, ML; Bellosillo, B; Besses, C; Burgaleta, C; Cervantes, F; Durán, MA; Ferrer-Marín, F; Gómez, M; Gómez-Casares, MT; Hernández-Boluda, JC; Marcote, B; Martínez-Avilés, L; Martínez-Trillos, A; Mata, MI; Senín, A; Vicente, V; Xicoy, B, 2014) |
| " From 1974 to 1986 we treated 20 symptomatic ET patients with microvascular circulation disturbances including erythromelalgia (N = 18), atypical or typical transient ischemic attacks (N = 6), or acute coronary ischemic syndrome (N = 3) with aspirin and one course of busulfan." | 5.09 | Normal life expectancy and thrombosis-free survival in aspirin treated essential thrombocythemia. ( Michiels, JJ, 1999) |
| "We have previously demonstrated that hydroxyurea (HU) reduces the rate of vascular complications in patients with essential thrombocythaemia (ET) at high risk of thrombosis." | 5.09 | Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. ( Barbui, T; Finazzi, G; Rodeghiero, F; Ruggeri, M, 2000) |
| " Rats treated with busulfan to induce thrombocytopenia exhibited a 90% decrease in circulating platelets." | 3.69 | Involvement of nitric oxide and cyclooxygenase products in photoactivation-induced microvascular occlusion. ( Lentsch, AB; Lindberg, RA; Miller, FN; Slaaf, DW, 1994) |
| "Treatment with busulfan or interferon-α is usually effective in hydroxyurea failures." | 2.48 | Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. ( Tefferi, A, 2012) |
| "Erythromelalgia was localized in the forefoot sole and toes in 28, the fingertips in 9, the handpalm in 2." | 2.39 | Erythromelalgic, thrombotic and hemorrhagic manifestations in 50 cases of thrombocythemia. ( Lindemans, J; Michiels, JJ; van Genderen, PJ; van Vliet, HH, 1996) |
| "The risk of major thrombosis is higher in ET patients aged more than 60 ys." | 2.39 | Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers. ( Barbui, T; Brière, J; Dupuy, E; Finazzi, G; Kiladjian, JJ, 1996) |
| "Risk of thrombosis is higher in JAK2-mutated ET." | 1.51 | Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. ( Barbui, T; Tefferi, A, 2019) |
| "Bleeding and thrombosis are frequent complications in myeloproliferative disorders (MPD) and are associated with severe organ damage and a high mortality." | 1.28 | Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients. ( Daum, I; Jamin, H; Schneider, W; Wehmeier, A, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (41.94) | 18.7374 |
| 1990's | 10 (32.26) | 18.2507 |
| 2000's | 2 (6.45) | 29.6817 |
| 2010's | 5 (16.13) | 24.3611 |
| 2020's | 1 (3.23) | 2.80 |
| Authors | Studies |
|---|---|
| Tefferi, A | 3 |
| Barbui, T | 5 |
| Alvarez-Larrán, A | 1 |
| Martínez-Avilés, L | 1 |
| Hernández-Boluda, JC | 1 |
| Ferrer-Marín, F | 1 |
| Antelo, ML | 1 |
| Burgaleta, C | 1 |
| Mata, MI | 1 |
| Xicoy, B | 1 |
| Martínez-Trillos, A | 1 |
| Gómez-Casares, MT | 1 |
| Durán, MA | 1 |
| Marcote, B | 1 |
| Ancochea, A | 1 |
| Senín, A | 1 |
| Angona, A | 1 |
| Gómez, M | 1 |
| Vicente, V | 1 |
| Cervantes, F | 1 |
| Bellosillo, B | 1 |
| Besses, C | 1 |
| Nazha, A | 1 |
| Gerds, AT | 1 |
| Douglas, G | 1 |
| Harrison, C | 1 |
| Forsyth, C | 1 |
| Bennett, M | 1 |
| Stevenson, W | 1 |
| Hounsell, J | 1 |
| Ratnasingam, S | 1 |
| Ritchie, D | 1 |
| Ross, DM | 1 |
| Grigg, A | 1 |
| Nakamae, H | 1 |
| Yamane, T | 1 |
| Hasegawa, T | 1 |
| Nakamae, M | 1 |
| Terada, Y | 1 |
| Hagihara, K | 1 |
| Ohta, K | 1 |
| Hino, M | 1 |
| Brodsky, I | 1 |
| Lindberg, RA | 1 |
| Slaaf, DW | 1 |
| Lentsch, AB | 1 |
| Miller, FN | 1 |
| Michiels, JJ | 3 |
| van Genderen, PJ | 1 |
| Lindemans, J | 1 |
| van Vliet, HH | 1 |
| Finazzi, G | 3 |
| Dupuy, E | 1 |
| Kiladjian, JJ | 1 |
| Brière, J | 1 |
| Heis, N | 1 |
| Rintelen, C | 1 |
| Gisslinger, B | 1 |
| Knöbl, P | 1 |
| Lechner, K | 1 |
| Gisslinger, H | 1 |
| Randi, ML | 1 |
| Rossi, C | 1 |
| Fabris, F | 1 |
| Menapace, L | 1 |
| Girolami, A | 1 |
| Ruggeri, M | 1 |
| Rodeghiero, F | 2 |
| Pearson, TC | 1 |
| Wetherley-Mein, G | 1 |
| Hussain, S | 1 |
| Grossi, A | 1 |
| Vannucchi, AM | 1 |
| Longo, G | 1 |
| Rafanelli, D | 1 |
| Rossi Ferrini, P | 1 |
| Scheffer, MG | 1 |
| Simoons, ML | 1 |
| Roelandt, JR | 1 |
| Wehmeier, A | 1 |
| Daum, I | 1 |
| Jamin, H | 1 |
| Schneider, W | 1 |
| Cortelazzo, S | 1 |
| Viero, P | 1 |
| D'Emilio, A | 1 |
| Niikura, H | 1 |
| Bernadou, A | 1 |
| Clauvel, JP | 1 |
| Antebi, L | 1 |
| Bilski-Pasquier, G | 1 |
| Lèques, B | 1 |
| Texier, L | 1 |
| Verdaguer, S | 1 |
| Hoffman-Martinot, R | 1 |
| Paulet, C | 1 |
| Moine, M | 1 |
| Rorvik, TO | 1 |
| Rudowski, W | 1 |
| Klawe, Z | 1 |
| Woźniewska, M | 1 |
| Ziemski, JM | 1 |
| Jamshidi, K | 1 |
| Ansari, A | 1 |
| Windschitl, HE | 1 |
| Swaim, WR | 1 |
| Silverstein, MN | 1 |
| Ravich, RB | 1 |
| Gunz, FW | 1 |
| Thompson, IL | 1 |
| Reed, CS | 1 |
| Benkö, S | 1 |
| Benkö, K | 1 |
| Török, L | 1 |
| Vallée, G | 1 |
| Boivin, P | 1 |
| Dormont, J | 1 |
| Soulier, JP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Retrospective and Prospective Multicenter Study Evaluating the Impact of Treatment With Cytoreducing Agents on the Recurrence of Thrombosis in Thrombotic Patients With a Diagnosis of Myeloproliferative Neoplasia and Normal Blood Counts - a FIM Study[NCT04539678] | 200 participants (Anticipated) | Observational | 2019-05-21 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for busulfan and Blood Clot
| Article | Year |
|---|---|
Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management.
Topics: Busulfan; Female; Humans; Janus Kinase 2; Leukemia, Myeloid, Acute; Leukocytosis; Male; Microcircula | 2023 |
Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera?
Topics: Busulfan; Cell Proliferation; Humans; Hydroxyurea; Janus Kinase 2; Leukemia, Myeloid, Acute; Nitrile | 2016 |
Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
Topics: Acute Disease; Age Factors; Alkylating Agents; Anticoagulants; Aspirin; Busulfan; Disease Management | 2012 |
Erythromelalgic, thrombotic and hemorrhagic manifestations in 50 cases of thrombocythemia.
Topics: Adult; Aged; Aspirin; Busulfan; Double-Blind Method; Erythromelalgia; Female; Gangrene; Hemorrhage; | 1996 |
Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers.
Topics: Adult; Aged; Alkylating Agents; Anemia, Megaloblastic; Arrhythmias, Cardiac; Bone Marrow Diseases; B | 1996 |
Disorders of hemostasis and thrombosis in the aged.
Topics: Adolescent; Adult; Aged; Aortic Aneurysm; Blood Coagulation Disorders; Blood Coagulation Factors; Bl | 1976 |
[Essential thrombocythemia: conventional therapy].
Topics: Adult; Antineoplastic Agents; Busulfan; Follow-Up Studies; Hemorrhage; Humans; Hydroxyurea; Immunolo | 1991 |
[Thrombosis in various diseases: myeloproliferative disorders].
Topics: Aspirin; beta-Thromboglobulin; Blood Coagulation Factors; Busulfan; Carbazilquinone; Dipyridamole; H | 1986 |
4 trials available for busulfan and Blood Clot
| Article | Year |
|---|---|
Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.
Topics: Aged; Aged, 80 and over; Alkylating Agents; Blood Cell Count; Busulfan; Comorbidity; Disease Progres | 2014 |
Normal life expectancy and thrombosis-free survival in aspirin treated essential thrombocythemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Busulfan; Coronary Disease; Dise | 1999 |
Aspirin seems as effective as myelosuppressive agents in the prevention of rethrombosis in essential thrombocythemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Busulfan; Disease-Free Survival; Female; Hemorr | 1999 |
Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Busul | 2000 |
19 other studies available for busulfan and Blood Clot
| Article | Year |
|---|---|
Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
Topics: Adult; Aspirin; Bone Marrow; Busulfan; Disease Management; Disease Progression; Hemorrhage; Humans; | 2019 |
Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyurea.
Topics: Antineoplastic Agents, Alkylating; Busulfan; Drug Resistance, Neoplasm; Drug Tolerance; Female; Foll | 2017 |
Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Aged; Busulfan; Disease-Free Survival; Evaluation Studies as Topic; Female; Graft | 2006 |
Busulphan: effect on platelet RNA dependent DNA polymerase--implications in the treatment of polycythemia vera, thrombosis and atherosclerosis.
Topics: Arteriosclerosis; Blood Platelets; Busulfan; Humans; Polycythemia Vera; RNA-Directed DNA Polymerase; | 1982 |
Involvement of nitric oxide and cyclooxygenase products in photoactivation-induced microvascular occlusion.
Topics: Amino Acid Oxidoreductases; Animals; Arterioles; Blood Platelets; Busulfan; Cyclooxygenase Inhibitor | 1994 |
The effect of interferon alpha on myeloproliferation and vascular complications in polycythemia vera.
Topics: Adult; Aged; Aged, 80 and over; Busulfan; Drug Tolerance; Erysipelas; Erythropoiesis; Female; Hemato | 1999 |
Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia.
Topics: Adult; Aged; Blood Cell Count; Blood Platelets; Bloodletting; Busulfan; Erythrocytes; Female; Hemato | 1978 |
Thrombocythemia and coronary artery disease.
Topics: Adult; Aged; Aspirin; Busulfan; Coronary Disease; Female; Humans; Male; Middle Aged; Polycythemia Ve | 1991 |
Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients.
Topics: Bloodletting; Busulfan; Cause of Death; Hemorrhage; Humans; Incidence; Leukemia, Myelogenous, Chroni | 1991 |
Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Busulfan; Cohort Studies; Female; Follow-Up Studies; Hem | 1990 |
[Vaquez's diseas. Clinical and developmental study. Apropos of 144 cases].
Topics: Adult; Arteriosclerosis; Arteritis; Blood Sedimentation; Busulfan; Child; Erythrocyte Count; Female; | 1968 |
[A new etiology of inflammatory livedo: thrombocytosis].
Topics: Arteritis; Busulfan; Diagnosis, Differential; Erythromelalgia; Female; Foot Dermatoses; Humans; Hydr | 1969 |
[Polycythemia vera].
Topics: Busulfan; Chronic Disease; Diagnosis, Differential; Hemorrhage; Humans; Phosphorus Radioisotopes; Po | 1974 |
Major surgery in patients with polycythaemia vera.
Topics: Aged; Blood Platelets; Blood Transfusion, Autologous; Bloodletting; Busulfan; Erythrocyte Count; Fem | 1974 |
Primary thrombocythemia.
Topics: Adult; Aged; Blood Coagulation Tests; Bone Marrow Examination; Busulfan; Follow-Up Studies; Gastroin | 1973 |
Primary or hemorrhagic thrombocythemia.
Topics: Adult; Anemia, Hypochromic; Busulfan; Female; Gastrointestinal Hemorrhage; Humans; Leukocytosis; Mal | 1968 |
The dangers of surgery in uncontrolled haemorrhagic thrombocythaemia.
Topics: Aged; Blood Cell Count; Blood Platelets; Busulfan; Hemorrhage; Humans; Male; Middle Aged; Peptic Ulc | 1970 |
Effects of a cytostatic agent and of a fibrinstabilizing factor on atherosclerosis in the rabbit.
Topics: Animals; Aorta; Arteriosclerosis; Blood Cell Count; Blood Coagulation Tests; Blood Platelets; Blood | 1970 |
[Present treatment of the Vaquez's disease].
Topics: Aged; Anemia; Anticoagulants; Antineoplastic Agents; Blood Donors; Blood Volume; Bloodletting; Busul | 1969 |